Last month, new legislation was overwhelmingly passed to expand the scope of the Committee on Foreign Investment in the United States (CFIUS). Two versions are currently being hashed out, but whatever the outcome, it will impact private equity through stricter oversight of cross-border investment, probably including at least some new restrictions on the transfer of minority interests. At present, the committee only considers buyouts.
A&M’s James Dubow and Eric Wang weigh in on how to handle an expected increase in supply chain-related efficiency problems.
This article was previously published in the July 5, 2018 issue of Asian Venture Capital Journal.
Section 232 Pharmaceutical Duties: UK Rate Cut to Zero, and the Origin and Section 301 Questions That Follow
August 5, 2026
Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.
Enterprise Management Incentive Plans - Recent Changes and Common Pitfalls
August 5, 2026
Enterprise Management Incentive (EMI) option plans have been at the centre of UK employee incentivisation for many years and remain popular with privately owned, fast-growing companies.
Better Data, Better Exits: The New Playbook for Wealth and Insurance Platform Roll-Ups
August 5, 2026
There’s a new value creation imperative for private equity (PE) firms and corporates seeking to roll up financial technology (FinTech) and data platform acquisitions, especially in the extended higher interest rate environment. Many of the traditional value enhancement strategies still matter, but operational platforming—integrating tech, data, and systems—can be a defining competitive advantage in roll-ups.
Lee Health is Transforming Growth Into a Truly Integrated Health System
August 4, 2026
Healthcare transformation isn't just about growing. It's about creating a system where patients experience coordinated, seamless care.
